Aridis Pharmaceuticals Inc.

5.82+0.1800+3.19%Vol 11.40K1Y Perf -3.49%
Apr 19th, 2021 16:00 DELAYED
BID5.61 ASK5.85
Open5.70 Previous Close5.64
Pre-Market- After-Market-
 - -  - -%
Target Price
17.20 
Analyst Rating
Strong Buy 1.00
Potential %
195.53 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap65.35M 
Earnings Rating
Neutral
Price Range Ratio 52W %
20.44 
Earnings Date
11th May 2021

Today's Price Range

5.555.92

52W Range

4.7010.18

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
9.81%
1 Month
-17.33%
3 Months
-19.72%
6 Months
-24.71%
1 Year
-3.49%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ARDS5.820.18003.19
AAPL134.840.68000.51
GOOG2 302.404.64000.20
MSFT258.74-2.0000-0.77
XOM56.48-0.1800-0.32
WFC43.880.04000.09
JNJ162.690.45000.28
FB302.24-3.9400-1.29
GE13.460.07000.52
JPM152.65-0.6500-0.42
ProfitabilityValueIndustryS&P 500US Markets
-
-2 226.70
-2 193.00
-1 835.50
-
RevenueValueIndustryS&P 500US Markets
1.00M
0.09
-13.37
-
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.54-0.59-9.26
Q03 2020-0.55-0.65-18.18
Q02 2020-0.72-0.4734.72
Q01 2020-0.62-0.73-17.74
Q04 2019--0.63-
Q03 2019-0.86-0.87-1.16
Q02 2019-1.09-1.035.50
Q01 2019-0.82-0.99-20.73
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.5876.13Positive
6/2021 QR-0.5286.73Positive
12/2021 FY-2.30--
12/2022 FY-1.07--
Next Report Date11th May 2021
Estimated EPS Next Report-0.58
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume11.40K
Shares Outstanding11.23M
Trades Count91
Dollar Volume239.73K
Avg. Volume30.50K
Avg. Weekly Volume12.81K
Avg. Monthly Volume31.05K
Avg. Quarterly Volume33.00K

Aridis Pharmaceuticals Inc. (NASDAQ: ARDS) stock closed at 5.82 per share at the end of the most recent trading day (a 3.19% change compared to the prior day closing price) with a volume of 11.40K shares and market capitalization of 65.35M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 32 people. Aridis Pharmaceuticals Inc. CEO is Vu Truong.

The one-year performance of Aridis Pharmaceuticals Inc. stock is -3.49%, while year-to-date (YTD) performance is -4.12%. ARDS stock has a five-year performance of %. Its 52-week range is between 4.7 and 10.18, which gives ARDS stock a 52-week price range ratio of 20.44%

Aridis Pharmaceuticals Inc. currently has a PE ratio of -2.30, a price-to-book (PB) ratio of 15.71, a price-to-sale (PS) ratio of 65.38, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -103.67%, a ROC of -770.63% and a ROE of 885.35%. The company’s profit margin is -%, its EBITDA margin is -2 193.00%, and its revenue ttm is $1.00 Million , which makes it $0.09 revenue per share.

Of the last four earnings reports from Aridis Pharmaceuticals Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.58 for the next earnings report. Aridis Pharmaceuticals Inc.’s next earnings report date is 11th May 2021.

The consensus rating of Wall Street analysts for Aridis Pharmaceuticals Inc. is Strong Buy (1), with a target price of $17.2, which is +195.53% compared to the current price. The earnings rating for Aridis Pharmaceuticals Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aridis Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aridis Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 16.91, ATR14 : 0.55, CCI20 : -38.89, Chaikin Money Flow : -0.45, MACD : -0.35, Money Flow Index : 51.07, ROC : -1.36, RSI : 49.83, STOCH (14,3) : 48.06, STOCH RSI : 1.00, UO : 46.05, Williams %R : -51.94), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aridis Pharmaceuticals Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (100.00 %)
5 (100.00 %)
5 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Aridis Pharmaceuticals Inc.

Aridis Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is engaged in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections.

CEO: Vu Truong

Telephone: +1 408 385-1742

Address: 5941 Optical Court, San Jose 95138, CA, US

Number of employees: 32

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

56%44%

Bearish Bullish

58%42%

Bearish Bullish

47%53%

News

Stocktwits